SWX:ROG.S

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche said its experimental MS drug fenebrutinib met the main goal in a late-stage study for primary progressive multiple sclerosis, showing “non-inferiority” to Ocrevus but with more frequent, reversible liver enzyme elevations and a higher share of fatal cases. Roche shares last closed down 0.6% at 356.40 francs. Investors await Monday’s webcast for more data and filing plans.

8 February 2026

Biotechnology·Healthcare News·Pharmaceuticals·Stock Market·SWX:ROG.S

Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results

Roche shares closed up 0.93% at 348.90 francs Friday after Goldman Sachs raised its rating to neutral and boosted its price target to 365 francs, citing lower-risk clinical catalysts in 2026. UBS lifted its target to 384 francs, while Deutsche Bank held at 325. The SMI fell 0.5%. Swiss markets reopen Monday.

17 January 2026

Earnings Reports·Pharmaceuticals·Stock Market·SWX:ROG.S

Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

Roche shares closed up 0.4% at 340.80 Swiss francs after MediLink announced a $570 million licensing deal for cancer drug YL201, granting Roche ex-China rights. The agreement includes additional milestone payments and royalties. Investors are watching Roche’s Jan. 12 conference and Jan. 29 earnings for further details.

10 January 2026

Pharmaceuticals·Stock Market·SWX:ROG.S

European Stocks Rise as Oil Prices Drop and Rate Hike Bets Grow
March 20, 2026, 5:11 AM EDT. European stocks rebounded on Friday, led by banking and construction sectors, as oil prices eased from recent highs above $119 a barrel. The decline followed U.S. signals about possibly lifting sanctions on Iranian crude to reduce energy costs. Central banks across Europe, including the European Central Bank (ECB) and Bank of England (BoE), held interest rates steady amid uncertainty from the U.S.-Iran conflict but traders increased bets on further rate hikes later this year. The ECB highlighted inflation risks tied to the war, while the BoE's unanimous hold hinted at readiness to act. Meanwhile, Unilever disclosed talks to sell part of its foods business to McCormick & Company, adding corporate activity amid market shifts.